Breaking News

Tuesday
Show Full Stories

X

To view all stories in expanded form, please subscribe.
Send Info
Hot Stocks
Natera files false advertising counterclaim against CareDx » 09:26
02/18/20
02/18
09:26
02/18/20
09:26
NTRA

Natera

$35.59 /

+0.58 (+1.66%)

, CDNA

CareDx

$26.67 /

+1.71 (+6.85%)

Natera (NTRA) announced…

Natera (NTRA) announced it has filed suit against CareDx (CDNA) for false advertising in the U.S. District Court for Delaware, alleging CareDx used false and misleading claims to deceive physicians about the performance capabilities of its AlloSure test, in violation of the Lanham Act and various Delaware laws prohibiting unfair competition and deceptive trade practices. "The DART trial and Medicare's approval of AlloSure relied on exceeding a 1% donor-derived cell-free DNA test-positive threshold to classify patients with active rejection. CareDx's advertising materials inappropriately manipulate dd-cfDNA thresholds to mislead physicians about AlloSure's negative predictive value and positive predictive value. CareDx conceals the interplay between PPV and NPV, routinely showing one performance value without the other corresponding value to mislead physicians about the performance of AlloSure. In addition to manipulating dd-cfDNA thresholds to bolster performance metrics, CareDx attempts to mislead physicians about the performance of AlloSure 3.0 in detecting T cell-mediated rejection, which accounts for 30% of all rejections. An independent peer-reviewed manuscript published in 2019 confirms AlloSure's inability to detect TCMR stating, we found that dd-cfDNA was not able to discriminate CMR from no rejection."

ShowHide Related Items >><<
03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

Over a week ago
Hot Stocks
Natera, Elicio Therapeutics to collaborate in Phase I/II study of ELI-002 » 09:17
02/11/20
02/11
09:17
02/11/20
09:17
NTRA

Natera

$35.36 /

-0.15 (-0.42%)

Elicio Therapeutics…

Elicio Therapeutics announced their collaboration in a prospective, multicenter Phase 1/2 study of ELI-002, an Amphiphile immuno-oncology therapeutic targeting KRAS mutations in the adjuvant setting for patients with pancreatic ductal adenocarcinoma who have undergone neoadjuvant chemotherapy followed by pancreatectomy. IND submission for the 108-patient trial which will open at 10-12 US sites will be in the first half of 2020. Natera's tumor-informed and personalized ctDNA platform, Signatera, will be used to select eligible patients whose tumors harbor a mutant KRAS allele and are at high risk for relapse because they have detectable molecular residual disease, or MRD, post-surgery. Signatera will also be used to perform serial monitoring to assess the percentage of patients achieving MRD clearance throughout the study.

ShowHide Related Items >><<
03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

Hot Stocks
Elicio and Natera announce collaboration in prospective study of ELI-002 » 09:07
02/11/20
02/11
09:07
02/11/20
09:07
NTRA

Natera

$35.36 /

-0.15 (-0.42%)

Elicio Therapeutics and…

Elicio Therapeutics and Natera (NTRA) announced their collaboration in a prospective, multicenter Phase 1/2 study of ELI-002, an Amphiphile immuno-oncology therapeutic targeting KRAS mutations in the adjuvant setting for patients with pancreatic ductal adenocarcinoma, or PDAC, who have undergone neoadjuvant chemotherapy followed by pancreatectomy. IND submission for the 108-patient trial which will open at 10-12 US sites will be in the first half of 2020. Natera's tumor-informed and personalized ctDNA platform, Signatera, will be used to select eligible patients whose tumors harbor a mutant KRAS allele and are at high risk for relapse because they have detectable molecular residual disease post-surgery. Signatera will also be used to perform serial monitoring to assess the percentage of patients achieving MRD clearance throughout the study.

ShowHide Related Items >><<
03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

Hot Stocks
CareDx announces patent rights upheld in Delaware court » 07:22
02/11/20
02/11
07:22
02/11/20
07:22
CDNA

CareDx

$24.26 /

+0.19 (+0.79%)

, NTRA

Natera

$35.36 /

-0.15 (-0.42%)

CareDx (CDNA) announced…

CareDx (CDNA) announced that on Magistrate Judge Christopher Burke of the U.S. District Court for the District of Delaware recommended the denial of Natera (NTRA) and Eurofins Viracor's motions to dismiss CareDx's patent infringement complaints against them. CareDx alleges that both Natera's and Viracor's organ transplant products infringe CareDx's patent rights. Natera and Viracor argued to the court that those patents are invalid because they allegedly cover ineligible subject matter. The court rejected their attack on the patents, explaining that the patents state that the invention is a "new, more accurate and useful analytic method" to help determine if a transplanted organ is rejected. The Court stated that the patents do not merely claim as the invention an unprotectable natural law.

ShowHide Related Items >><<
03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

Hot Stocks
Natera files patent infringement suit against ArcherDX » 09:14
01/27/20
01/27
09:14
01/27/20
09:14
NTRA

Natera

$35.71 /

-1.08 (-2.94%)

Natera filed suit against…

Natera filed suit against ArcherDX for infringement of Natera's U.S. Patent No. 10,538,814. The complaint was filed in the U.S. District Court of Delaware. The '814 patent is titled "Methods for Simultaneous Amplification of Target Loci" and was issued by the United States Patent and Trademark Office on January 21, 2020. The '814 patent claims methods for using multiplex polymerase chain reaction technology to simultaneously amplify multiple nucleic acid regions of interest in a single reaction before using high-throughput sequencing to characterize the nucleic acids. The '814 patent is one of more than 200 patents issued or pending in Natera's global intellectual property portfolio, including more than 60 in the field of oncology. Natera's complaint alleges that ArcherDX's sale and use of certain cell-free DNA-based oncology products infringes on the '814 patent. ArcherDX has introduced oncology products using multiplex PCR technology, including a tool for personalized cancer monitoring. Natera has the exclusive rights to perform and license personalized monitoring and MRD testing in oncology using its patented multiplex PCR technology. Natera is seeking injunctive relief and monetary damages.

ShowHide Related Items >><<
03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

Conference/Events
American Society of Clinical Oncology to hold a symposium » 04:55
01/25/20
01/25
04:55
01/25/20
04:55
AMZN

Amazon.com

$1,862.09 /

-22.76 (-1.21%)

, AGIO

Agios Pharmaceuticals

$53.04 /

-0.22 (-0.41%)

, AZN

AstraZeneca

$49.28 /

-0.93 (-1.85%)

, BAYRY

Bayer

$0.00 /

+ (+0.00%)

, BMY

Bristol-Myers

$64.18 /

-2.715 (-4.06%)

, CELG

Bought by BMY

$0.00 /

+ (+0.00%)

, DNA

Bought by RHHBY

$0.00 /

+ (+0.00%)

, DSNKY

Daiichi Sankyo

$0.00 /

+ (+0.00%)

, ERYP

Erytech Pharma

$7.10 /

+ (+0.00%)

, ESALY

Eisai

$0.00 /

+ (+0.00%)

, EXEL

Exelixis

$18.01 /

-1.57 (-8.02%)

, FGEN

FibroGen

$41.80 /

-2.35 (-5.32%)

, HSDEF

Harborside

$0.00 /

+ (+0.00%)

, INCY

Incyte

$76.66 /

-1.56 (-1.99%)

, LXRX

Lexicon

$3.37 /

-0.07 (-2.03%)

, MRK

Merck

$85.96 /

-2.56 (-2.89%)

, NTRA

Natera

$35.71 /

-1.08 (-2.94%)

, NVTA

Invitae

$18.35 /

-0.15 (-0.81%)

, PFE

Pfizer

$39.82 /

-0.89 (-2.19%)

, PGNX

Progenics

$4.65 /

-0.045 (-0.96%)

, SGEN

Seattle Genetics

$113.63 /

-1.69 (-1.47%)

, TROV

Trovagene

$1.69 /

-0.075 (-4.25%)

2020 Gastrointestinal…

2020 Gastrointestinal Cancers Symposium will be held in San Francisco on January 23-25.

ShowHide Related Items >><<
03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

Over a month ago
Conference/Events
American Society of Clinical Oncology to hold a symposium » 04:55
01/24/20
01/24
04:55
01/24/20
04:55
AMZN

Amazon.com

$1,884.85 /

-2.47 (-0.13%)

, AGIO

Agios Pharmaceuticals

$53.26 /

-0.54 (-1.00%)

, AZN

AstraZeneca

$50.21 /

-0.24 (-0.48%)

, BAYRY

Bayer

$0.00 /

+ (+0.00%)

, BMY

Bristol-Myers

$66.89 /

-0.53 (-0.79%)

, CELG

Bought by BMY

$0.00 /

+ (+0.00%)

, DNA

Bought by RHHBY

$0.00 /

+ (+0.00%)

, DSNKY

Daiichi Sankyo

$0.00 /

+ (+0.00%)

, ERYP

Erytech Pharma

$7.10 /

-0.13 (-1.80%)

, ESALY

Eisai

$0.00 /

+ (+0.00%)

, EXEL

Exelixis

$19.58 /

-0.14 (-0.71%)

, FGEN

FibroGen

$44.15 /

+0.37 (+0.85%)

, HSDEF

Harborside

$0.00 /

+ (+0.00%)

, INCY

Incyte

$78.22 /

-0.25 (-0.32%)

, LXRX

Lexicon

$3.44 /

-0.33 (-8.75%)

, MRK

Merck

$88.52 /

-1.13 (-1.26%)

, NTRA

Natera

$36.79 /

-0.37 (-1.00%)

, NVTA

Invitae

$18.50 /

-0.265 (-1.41%)

, PFE

Pfizer

$40.71 /

+0.52 (+1.29%)

, PGNX

Progenics

$4.70 /

+0.03 (+0.64%)

, SGEN

Seattle Genetics

$115.32 /

+3.61 (+3.23%)

, TROV

Trovagene

$1.77 /

+0.035 (+2.02%)

2020 Gastrointestinal…

2020 Gastrointestinal Cancers Symposium will be held in San Francisco on January 23-25.

ShowHide Related Items >><<
03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

Conference/Events
American Society of Clinical Oncology to hold a symposium » 08:12
01/23/20
01/23
08:12
01/23/20
08:12
AMZN

Amazon.com

$1,887.32 /

-4.96 (-0.26%)

, AGIO

Agios Pharmaceuticals

$53.80 /

+0.01 (+0.02%)

, AZN

AstraZeneca

$50.45 /

-0.345 (-0.68%)

, BAYRY

Bayer

$0.00 /

+ (+0.00%)

, BMY

Bristol-Myers

$67.42 /

-0.01 (-0.01%)

, CELG

Bought by BMY

$0.00 /

+ (+0.00%)

, DNA

Bought by RHHBY

$0.00 /

+ (+0.00%)

, DSNKY

Daiichi Sankyo

$0.00 /

+ (+0.00%)

, ERYP

Erytech Pharma

$7.23 /

+ (+0.00%)

, ESALY

Eisai

$0.00 /

+ (+0.00%)

, EXEL

Exelixis

$19.72 /

-0.04 (-0.20%)

, FGEN

FibroGen

$43.78 /

+0.8 (+1.86%)

, HSDEF

Harborside

$0.00 /

+ (+0.00%)

, INCY

Incyte

$78.47 /

-0.22 (-0.28%)

, LXRX

Lexicon

$3.77 /

-0.28 (-6.91%)

, MRK

Merck

$89.65 /

-0.31 (-0.34%)

, NTRA

Natera

$37.16 /

+0.01 (+0.03%)

, NVTA

Invitae

$18.77 /

-0.025 (-0.13%)

, PFE

Pfizer

$40.19 /

-0.17 (-0.42%)

, PGNX

Progenics

$4.67 /

+0.015 (+0.32%)

, SGEN

Seattle Genetics

$111.71 /

+3.04 (+2.80%)

, TROV

Trovagene

$1.73 /

+0.18 (+11.61%)

2020 Gastrointestinal…

2020 Gastrointestinal Cancers Symposium will be held in San Francisco on January 23-25.

ShowHide Related Items >><<
03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

Hot Stocks
Natera filed suit against CareDx for patent infringement » 09:28
01/13/20
01/13
09:28
01/13/20
09:28
NTRA

Natera

$33.50 /

-0.15 (-0.45%)

Natera filed suit against…

Natera filed suit against CareDx for infringing its U.S. Patent 10,526,658. The U.S. Patent Office most recently recognized Natera's innovation in cell-free DNA, or cfDNA, when it awarded the '658 patent on January 7th, 2020. The '658 patent covers cfDNA-based diagnostic methods, including those for transplant. Natera now has over 200 patents issued and pending, including more than twenty in the field of transplant. In recent studies separately evaluating Prospera and Allosure, Prospera had an 89% sensitivity for rejection, compared with a 59% sensitivity for Allosure.1 Natera's NPV was 95%, compared with 84% for Allosure, in a similar incidence cohort.1,2 Additionally, Prospera detected 10/10 T Cell-Mediated Rejection samples while Allosure could only identify 3/11.2

ShowHide Related Items >><<
03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

Hot Stocks
CareDx announces false advertising complaint upheld by court » 07:07
01/08/20
01/08
07:07
01/08/20
07:07
CDNA

CareDx

$20.30 /

-0.59 (-2.82%)

, NTRA

Natera

$34.98 /

+1.19 (+3.52%)

CareDx (CNDA) announced…

CareDx (CNDA) announced that on December 20, 2019, Magistrate Judge Christopher Burke issued a report recommending that the U.S. District Court for the District of Delaware reject Natera (NTRA) motion to dismiss CareDx's false advertising complaint. CareDx filed suit against Natera on April 10, 2019, alleging that Natera's comparison of its kidney transplant technology to CareDx's AlloSure technology improperly and misleadingly compares the results of two independent studies with differing methodologies. AlloSure's performance was validated by CareDx's robust, multi-center, prospective, peer-reviewed clinical trial. In contrast, Natera's study of its transplant technology used samples retrospectively selected from a single center, improperly mixed population sets, and failed to adhere to internationally accepted criteria for kidney transplant rejection studies. The company said, "CareDx is pleased the court recommended that its false advertising claims against Natera should go forward because they are legally supported. CareDx will continue to pursue its claims and is seeking all available remedies, including monetary damages. In addition, CareDx is continuing to pursue its patent infringement case against Natera."

ShowHide Related Items >><<
03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

Get Full Fly Access

Breaking market intelligence sent straight to you
Our team of experts analyze every news story and filter out the noise to deliver real-time market moving news.
Up-to-date information on important industry events
Get real-time updates on events that are moving the market—from conferences and calls to syndicate announcements.
News focused on the companies in your portfolio
Create up to 12 portfolios with 150 stocks each, and see how active they are in market news.